Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: RARE

Ultragenyx Pharmaceutical Inc.

Healthcare | Biotechnology

No licensed closing price on file for RARE. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$-5.83

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) is a biotechnology company. Figures from SEC EDGAR; updated 2026-11-09 03:49 UTC.

What Ultragenyx Pharmaceutical Inc. does

The company develops product candidates that must obtain regulatory approval from the U.S. FDA and other jurisdictions before commercialization, a process requiring compliance with requirements regarding safety, efficacy, manufacturing, clinical studies, and distribution. Regulatory approval policies, review timelines, and communication with agencies are unpredictable, and approval granted in one jurisdiction does not ensure approval elsewhere.

Summarized from Ultragenyx Pharmaceutical Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Valuation
EPS (TTM)$-5.83

Revenue, margins & earnings

FY2021: net loss $454M on revenue $351M$351MFY2021FY2022: net loss $707M on revenue $363M$363MFY2022FY2023: net loss $607M on revenue $434M$434MFY2023FY2024: net loss $569M on revenue $560M$560MFY2024FY2025: net loss $575M on revenue $673M$673MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-10-19
  • 2026-10-19Chief Financial OfficerSale-7,066$107.9K
  • 2026-09-15SVP, Chief Accounting OfficerSale-1,283$17.4K
  • 2026-09-08SVP, Chief Accounting OfficerSale-161$2.3K
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Ultragenyx Pharmaceutical Inc. do?

The company develops product candidates that must obtain regulatory approval from the U.S.

When did RARE last file with the SEC?

Ultragenyx Pharmaceutical Inc.'s most recent SEC filing on record is a 8-K filed 2026-05-18. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-11-09 03:49 UTC. This page is also available as JSON at /api/data?ticker=RARE and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for RARE and 5,000+ tickers.

Create a free account — keep RARE
For your agent
GET /api/data?ticker=RARE

This page as JSON via rel="alternate" · REST API docs · MCP server (63 tools) · llms.txt